Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Sees Significant Decline in Short Interest
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 5,900 shares, a decrease of 50.0% from the December 15th total of 11,800 shares. Based on an average daily volume of 51,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company’s shares are sold short.
Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 11th.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC acquired a new stake in shares of Opiant Pharmaceuticals during the 3rd quarter worth about $90,000. Morgan Stanley increased its position in Opiant Pharmaceuticals by 39.1% during the third quarter. Morgan Stanley now owns 10,714 shares of the technology company’s stock worth $80,000 after acquiring an additional 3,012 shares during the period. Acadian Asset Management LLC increased its position in Opiant Pharmaceuticals by 90.8% during the third quarter. Acadian Asset Management LLC now owns 62,048 shares of the technology company’s stock worth $464,000 after acquiring an additional 29,527 shares during the period. BlackRock Inc. increased its position in Opiant Pharmaceuticals by 43.6% during the third quarter. BlackRock Inc. now owns 29,491 shares of the technology company’s stock worth $220,000 after acquiring an additional 8,948 shares during the period. Finally, GSA Capital Partners LLP increased its position in Opiant Pharmaceuticals by 100.4% during the third quarter. GSA Capital Partners LLP now owns 27,110 shares of the technology company’s stock worth $203,000 after acquiring an additional 13,583 shares during the period. Institutional investors and hedge funds own 19.32% of the company’s stock.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings data on Thursday, November 12th. The technology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.34. Opiant Pharmaceuticals had a net margin of 25.32% and a negative return on equity of 2.43%. The company had revenue of $9.11 million during the quarter, compared to the consensus estimate of $7.94 million. As a group, sell-side analysts predict that Opiant Pharmaceuticals will post -0.83 earnings per share for the current fiscal year.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
See Also: Quiet Period Expirations
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.